Earlier versions of this investigational vaccine contained proteins from four strains of flu; the new vaccine has proteins from six .

Friday, September 15, 2023 NIH Clinical Trial of Universal Flu Vaccine Candidate Begins Researchers at the National Institute of Allergy and Infectious Diseases, part of the NIH, have begun a Phase 1 trial to test the safety and immunogenicity of a new experimental universal influenza vaccine. The vaccine is designed to induce an immune response against many different influenza virus strains by displaying part of the influenza virus hemagglutinin (HA) protein on self-assembling nanoparticle scaffolds. Exposure to these harmless fragments of virus proteins prepares the immune system to recognize and fight against the actual virus, in case of a flu infection. Earlier versions of this investigational vaccine contained HA from four strains of flu; the new vaccine has proteins from six strains. National Institute of Allergy and Infectious Diseases  |  National Institutes of Health Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help. This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).                             This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107